Available experimental data confirm that LMP1 can increase PD-L1 expression on the surface of tumor cells and antigen-presenting cells, which consequently promotes the silencing of the immune response, enhances immunosuppression, and facilitates the progression of CLL23,26–28,32–34. Here, PDLIM7 is linked to neoplasm.